Avalo Therapeutics, Inc.
AVTXCIK 0001534120 · Pharmaceutical Preparations · Nasdaq
- Cerecor Inc. (until 2021-08-18)
Revenue (TTM)
$249K
−86.6% YoY
Q1 May 2026
Net Income (TTM)
−$84.17M
−122.8% YoY
Q1 May 2026
EPS Diluted (TTM)
−$6.34
+72.1% YoY
Q1 May 2026
Gross Margin
281.1%
Q1 May 2026
Operating Margin
-29,752.6%
Q1 May 2026
Net Margin
-33,802.8%
Q1 May 2026
Free Cash Flow (TTM)
−$43.59M
Q1 May 2026
Cash
$24.99M
Q1 May 2026
Total Debt
$15.3M
Q1 May 2026
Shares Outstanding
52.57M sh
Q1 May 2026